ArticleJournal of virology2026
Completion of the 5' end of the porcine teschovirus genome reveals a functional S-segment and enables reverse genetics.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Porcine teschoviruses (PTVs) are swine-specific picornaviruses associated with neurological and systemic disease, ranging from severe paralytic Teschen disease to milder forms of porcine encephalomyelitis, known as Talfan disease. Despite their global distribution and veterinary relevance, complete genomic information and molecular tools for PTVs are not available. Here, we report the first complete genome sequences of PTV-A11 (strain Dresden) and a recent PTV-A field isolate (strain Gi2020_1). Both genomes, each approximately 7.2 kb in size, include a previously uncharacterized 5'-terminal region upstream of the poly(C) tract (S-segment), thereby elucidating the complete genomic architecture of PTVs for the first time. The conserved 117-118 nucleotide S-segment closes a long-standing gap in teschovirus genomics and is essential for viral replication. Using reverse genetics, we established infectious molecular clones of both strains that recapitulate the properties of their parental strains. These systems enabled functional analyses of viral gene products, including the demonstration that the leader protein is dispensable for genome replication and morphogenesis but contributes to efficient virus growth. In addition, we developed a replication-competent subgenomic replicon and engineered fluorescent reporter viruses, including a stable mCherry-expressing virus that supports robust infection analysis and allows quantitative protein expression measurements. Together, these findings define the complete PTV genome organization and provide a versatile molecular toolbox for studying teschovirus replication, pathogenesis, and control.IMPORTANCETeschen disease was once a devastating neurological disease of swine caused by highly virulent porcine teschovirus strains (PTVs) but has become rare following their eradication. Current control strategies base on hygiene measures and herd-specific vaccination providing limited protection and leaving swine populations vulnerable to the (re-)emergence of neuroinvasive PTVs. Less virulent strains remain endemic worldwide and continue to impair animal health, welfare, and production efficiency. Progress toward broadly effective vaccines and antivirals has been constrained by incomplete knowledge of the PTV genome. Here, we identify and functionally define the previously unrecognized S-segment that completes the 5' UTR of PTVs. We further established infectious cDNA clones and developed subgenomic replicons, leaderless viruses, and fluorescent reporter viruses. Our tools enable direct genetic manipulation of PTVs. They provide a platform for mechanistic studies of viral replication, attenuation, and antigen design supporting rational development of vaccines and antiviral strategies against emerging PTVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.